Cochrane Abstracts
Rituximab for myasthenia gravis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rituximab for Myasthenia Gravis." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440792/all/Rituximab_for_myasthenia_gravis.
Rituximab for myasthenia gravis. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440792/all/Rituximab_for_myasthenia_gravis. Accessed August 23, 2025.
Rituximab for myasthenia gravis. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440792/all/Rituximab_for_myasthenia_gravis
Rituximab for Myasthenia Gravis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 August 23]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440792/all/Rituximab_for_myasthenia_gravis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rituximab for myasthenia gravis
ID - 440792
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440792/all/Rituximab_for_myasthenia_gravis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
